Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sastry

Showing results (271-280 of 288) with videos related to

Pageof 29
Sort By:
Frontiers in Immunology|December 17, 2020
A Neutrophil-Driven Inflammatory Signature Characterizes the Blood Transcriptome Fingerprint of PsoriasisArun Rawat, Darawan Rinchai, Mohammed Toufiq, et al.
Advances in Therapy|July 12, 2022
Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label ExtensionRogério Souza, Marion Delcroix, Nazzareno Galié, et al.
Journal of Laboratory Physicians|June 5, 2019
Evaluation of performance of direct disk diffusion test from positively flagged blood culture broth: A large scale study from South IndiaDeepashree Rajshekar, Kavita V Chaudhari, Prasanna Bhat, et al.
Clinical Genetics|February 20, 2015
Characterization of patients referred for non-specific intellectual disability testing: the importance of autosomal genes for diagnosisC A Tan, S Topper, D Del Gaudio, et al.
Plos One|March 29, 2018
Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trialRogério Souza, Richard N Channick, Marion Delcroix, et al.
JACC. Heart Failure|December 3, 2014
Effect of macitentan on hospitalizations: results from the SERAPHIN trialRichard N Channick, Marion Delcroix, Hossein-Ardeschir Ghofrani, et al.
European Heart Journal|March 23, 2017
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertensionNazzareno Galiè, Pavel Jansa, Tomás Pulido, et al.
The European Respiratory Journal|October 24, 2015
Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHINGérald Simonneau, Richard N Channick, Marion Delcroix, et al.
Journal of Translational Medicine|May 13, 2020
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutatedMuna Al Hashmi, Konduru S Sastry, Lee Silcock, et al.
Bioorganic & Medicinal Chemistry|August 15, 2006
Substituent activity relationship studies on new azolo benzoxazepinyl oxazolidinonesJagattaran Das, M Sitaram Kumar, D Subrahmanyam, et al.
Pageof 29

Showing results (271-280 of 288) with videos related to

Sort By:
Pageof 29
Frontiers in Immunology|December 17, 2020
A Neutrophil-Driven Inflammatory Signature Characterizes the Blood Transcriptome Fingerprint of PsoriasisArun Rawat, Darawan Rinchai, Mohammed Toufiq, et al.
Advances in Therapy|July 12, 2022
Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label ExtensionRogério Souza, Marion Delcroix, Nazzareno Galié, et al.
Journal of Laboratory Physicians|June 5, 2019
Evaluation of performance of direct disk diffusion test from positively flagged blood culture broth: A large scale study from South IndiaDeepashree Rajshekar, Kavita V Chaudhari, Prasanna Bhat, et al.
Clinical Genetics|February 20, 2015
Characterization of patients referred for non-specific intellectual disability testing: the importance of autosomal genes for diagnosisC A Tan, S Topper, D Del Gaudio, et al.
Plos One|March 29, 2018
Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trialRogério Souza, Richard N Channick, Marion Delcroix, et al.
JACC. Heart Failure|December 3, 2014
Effect of macitentan on hospitalizations: results from the SERAPHIN trialRichard N Channick, Marion Delcroix, Hossein-Ardeschir Ghofrani, et al.
European Heart Journal|March 23, 2017
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertensionNazzareno Galiè, Pavel Jansa, Tomás Pulido, et al.
The European Respiratory Journal|October 24, 2015
Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHINGérald Simonneau, Richard N Channick, Marion Delcroix, et al.
Journal of Translational Medicine|May 13, 2020
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutatedMuna Al Hashmi, Konduru S Sastry, Lee Silcock, et al.
Bioorganic & Medicinal Chemistry|August 15, 2006
Substituent activity relationship studies on new azolo benzoxazepinyl oxazolidinonesJagattaran Das, M Sitaram Kumar, D Subrahmanyam, et al.
Pageof 29